San Francisco,9 October 2018: According
to a report by Grand View Research, Inc., global antisense
& RNAi therapeutics market is anticipated to value USD 1.81
billion by 2025. Growing requirement of advanced and effective therapeutics to
address rising cases of chronic disorders globally is anticipated to propel
demand for antisense & RNAi therapeutics. Antisense technology is likely to
offer an opportunity for manipulation of gene expression for treatment of
several diseases. It can be used to study gene function for disease management
by regulating expression of disease-causing gene.
Continual R&D for
treatment of uncommon neurodegenerative diseases such as hereditary ATTR
amyloidosis can influence growth of market. Development of antisense
therapeutics to overcome challenges related to unspecific modes of action and
delivery-associated complications can augment market growth over next few
years.
Difficulty in delivering drugs
to specific site is expected to become major challenge for use of antisense and
RNAi. Drug delivery to nervous tissues can be tough as the drug is supposed to
pass blood-brain barrier. In addition, inevitable toxic effects of using these
therapeutics can further restrict growth of market over the forecast period. It
is necessary to determine right dosage and composition of antisense molecule to
reduce Huntington's disease (HD) symptoms and avoid side effects.
Access
Research Report of Antisense
& RNAi Therapeutics Market@ www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
The antisense & RNAi
therapeutics market can be segregated on the basis of technology, application,
route of administration, and region. Based on technology, the market can be
categorized into RNA interference and antisense RNA. In 2016, antisense RNA
segment dominated the market and accounted for largest market share over the
forecast period. Growing use of antisense oligonucleotides to treat
neurodegenerative disorders is expected to fuel growth of segment. In addition,
implementation of various approaches for prevention of disease onset or halting
progressions can influence growth. Diseases such as spinal muscular atrophy and
amyotrophic lateral sclerosis are expected to show positive results with use of
antisense technology.
Based on application, the
market can be classified into oncology, cardiovascular, respiratory disorders,
renal diseases, neurodegenerative disorders, genetic disorders, infectious
diseases, and other. Oncology segment is expected to contribute maximum towards
growth of market over next few years. Rising cases of eradication disorders
such as cancer, HIV, and other mutating viral diseases can augment use of
oligonucleotide products. Growing number of clinical trials for oligonucleotide
drugs are likely to exhibit growth of segment. In addition, high prevalence of
significant pipeline for cancer therapies by companies and institutes can boost
segment growth over the forecast period. Moreover, R&D in nanocarriers for
oligonucleotide delivery can contribute well to cancer treatment. These
nanoparticles can be used to reduce toxicity.
Browse more reports of this category by
Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals
Based on route of
administration, the market can be divided into pulmonary delivery, intravenous
injections, intradermal injections, intraperitoneal injections, topical
delivery, and other delivery methods.
Regional segmentation includes
Europe, North America, Asia Pacific, Latin America, and Middle East &
Africa (MEA). In North America, the market is expected to witness significant
growth over the forecast period. Rising number of RNAi therapeutics currently
under developmental pipeline in United States can augment growth of market. Big
pharmaceutical developers are likely to enter into collaborations and licensing
deals with other smaller firms to boost revenue generation. This, in turn, can
fuel market growth over next few years.
Since the discovery of RNAi,
there have been efforts to improve treatment methods using RNAi. However, complexities
in delivery methodologies associated with RNAi is expected to slow down growth
of market. Development of new nanotechnology-oriented methods are likely to
re-infuse the market with growth potential during the forecast period.
Moreover, rising number of
drug candidates under clinical trials are expected to show favorable results
and can progress through development process. This, in turn, can augment market
growth over the forecast period.
Some of the leading companies
offering antisense & RNAi therapeutics are Olix Pharmaceuticals,
GlaxoSmithKline Plc, Alnylam Pharmaceuticals, Benitec Biopharma Ltd., and
Antisense Therapeutics Limited. These players are expected to be involved in
development of RNAi therapies and platforms that can offer diagnostics,
medicines, personalized treatment options for key diseases.
Access
Press Release of Antisense & RNAi Therapeutics Market@ www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment